Global Anticonvulsants Market, By Drug Class (Pyrimidinediones, Benzodiazepines, Fructose derivatives, Aromatic allylic alcohols, Valproylamides, Carboxamides, Bromides, Carbamates, Aldehydes, Sulfonamides, Pyrrolidines, Triazines, Fatty acids, Propionates, Oxazolidinediones, Hydantoins, Barbiturates, Others), Dosage (Tablet, Capsule, Liquid, Rectal Gel, Cream, Others), Route of Administration (Topical, Eternal, Parenteral), Application (Migraine, Epilepsy, Neuropathic pain, Anxiety, Fibromyalgia, Bipolar Disorder, Borderline Personality Disorder), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Industry Trends and Forecast to 2030.
Anticonvulsants Market Analysis and Size
Anticonvulsants are the pharmaceutical agents which are used for the treatment of epileptic seizures. They are also known as anti-epileptic drugs and anti-seizure drugs. These drugs are either classified as first generation agents and second generation agents. They act as a mood stabilizers and also used in the treatment of neuropathic pain.
Data Bridge Market Research analyses that the anticonvulsants market which was USD 6,757.80 million in 2022, is expected to reach USD 8,030.40 billion by 2030, and is likely to undergo a CAGR of 4.9% during the forecast period of 2023 to 2030. “Pyrimidinediones” dominates the drug class segment of the anticonvulsants market owing to the rising pharmaceutical industries with increasing prevalence of geriatric population. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Anticonvulsants Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Pyrimidinediones, Benzodiazepines, Fructose derivatives, Aromatic allylic alcohols, Valproylamides, Carboxamides, Bromides, Carbamates, Aldehydes, Sulfonamides, Pyrrolidines, Triazines, Fatty acids, Propionates, Oxazolidinediones, Hydantoins, Barbiturates, Others), Dosage (Tablet, Capsule, Liquid, Rectal Gel, Cream, Others), Route of Administration (Topical, Eternal, Parenteral), Application (Migraine, Epilepsy, Neuropathic pain, Anxiety, Fibromyalgia, Bipolar Disorder, Borderline Personality Disorder), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa
|
|
Market Players Covered
|
|
|
Market Opportunities
|
|
Market Definition
Antiepileptic medicines (AEDs), usually referred to as anticonvulsants, are a group of pharmaceutical pharmaceuticals principally used to prevent and treat epileptic seizures. These medications are made to suppress or lessen seizures in people with epilepsy, a neurological condition characterised by unpredictable, repeated seizures.
Global Anticonvulsants Market Dynamics
Drivers
- Increasing Prevalence of Epilepsy
One of the most prevalent neurological conditions worldwide is epilepsy. The need for anticonvulsant drugs rises as the incidence and prevalence of epilepsy continue to rise
- Rising Government Initiatives
Government-funded healthcare initiatives and programmes that improve access to epilepsy care and treatment can improve the business climate
- Increasing Geriatric Population
Neurological conditions such as epilepsy are more common in the senior population. The ageing population in many nations fuels the growth of the anticonvulsant medicine industry, which is helping to drive market growth
Opportunities
- Growing Demand of Personalized Medicine
Research developments in genetics and biomarkers enable more specialised treatment modalities. Anticonvulsant therapy can be customised to a patient's genetic profile to improve treatment outcomes
- Rising Development of Novel Therapies
There is continuing research into creating novel anticonvulsant medications that are more effective and have fewer negative effects. The launch of cutting-edge treatments may open up enormous business prospects
- Increasing Demand of Telemedicine
Technologies such as telemedicine and remote monitoring can improve patient care and treatment plan adherence. Particularly in isolated or disadvantaged locations, this may result in a rise in demand for anticonvulsant drugs
Restrains/ Challenges
- Strict Regulations
Due to regulatory constraints, the approval procedure for new anticonvulsant drugs can be difficult and time consuming. This may cause a delay in the delivery of treatments that might be helpful to patients
- Drug Resistance
Over time, some individuals may acquire a resistance to anticonvulsant drugs, making it difficult to successfully control their illness. This may necessitate the use of alternative therapies, such as surgical treatments
- Adverse Effects
Significant side effects of anticonvulsant drugs can include weight gain, tiredness, dizziness, and cognitive decline. Patient’s quality of life and adherence to therapy may be impacted by these adverse effects
- High Development Costs
Developing new anticonvulsant drugs is expensive and time-consuming. The pharmaceutical industry faces challenges in justifying the investment in research and development for these medications, especially for rarer forms of epilepsy
This anticonvulsants market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anticonvulsants market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth
Global Anticonvulsants Market Scope
The anticonvulsants market is segmented on the basis of drug class, dosage, route of administration, application, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
Drug Class
- Pyrimidinediones
- Benzodiazepines
- Fructose Derivatives
- Aromatic Allylic Alcohols
- Valproylamides
- Carboxamides
- Bromides
- Carbamates
- Aldehydes
- Sulfonamides
- Pyrrolidines
- Triazines
- Fatty Acids
- Propionates
- Oxazolidinediones
- Hydantoins
- Barbiturates
- Others
Dosage
- Tablet
- Capsule
- Liquid
- Rectal Gel
- Cream
- Others
Route of Administration
- Topical
- Eternal
- Parenteral
Application
- Migraine
- Epilepsy
- Neuropathic Pain
- Anxiety
- Fibromyalgia
- Bipolar Disorder
- Borderline personality Disorder
End-Users
- Clinics
- Hospitals
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Anticonvulsants Market Regional Analysis/Insights
Anticonvulsants market is analyzed and market size information is provided by the drug class, dosage, route of administration, application, end-users and distribution channel as referenced above.
The countries covered in the anticonvulsants market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa
North America dominates the anticonvulsants market due to the presence of rise in the incidence of bacterial infections, growing investment by major key players in the R&D activities, well-developed healthcare sector and increase in the number of product approvals in this region.
Asia-Pacific is expected to grow during the forecast period 2023 to 2030 due to the availability of azithromycin as a generic and branded drug, rapid progress of biopharmaceutical sector, increasing research and development activities, development in healthcare sector and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
Anticonvulsants market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Anticonvulsants Market Share Analysis
The anticonvulsants market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to global anticonvulsants market.
Some of the major players operating in the anticonvulsants market are:
- Novartis AG (Switzerland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Abbott (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bausch Health Companies Inc. (U.S.)
- UCB S.A. (Belgium)
- Sunovion Pharmaceuticals Inc. (U.S.)
- GW Pharmaceuticals plc (U.K.)
- AstraZeneca (U.K.)
- GlaxoSmithKline plc (U.K.)
- H. Lundbeck A/S (Denmark)
- Takeda Pharmaceutical Company Limited (Japan)
- Sumitomo Dainippon Pharma Co., Ltd (Japan)
- Biocon (India)
- Merck KGaA (Germany)
- Cadila Pharmaceuticals (India)
- Eisai Co., Ltd (Japan)
- Cipla Inc. (India)
- Glenmark Pharmaceuticals Limited (India)
- Mankind Pharma (India)
- Novo Nordisk A/S (Denmark)
- Otsuka America Pharmaceutical, Inc (Japan)
- WOCKHARDT (India)
SKU-